EP0921809A4 - Use of prolactin as a tgf-beta antagonist - Google Patents

Use of prolactin as a tgf-beta antagonist

Info

Publication number
EP0921809A4
EP0921809A4 EP97921467A EP97921467A EP0921809A4 EP 0921809 A4 EP0921809 A4 EP 0921809A4 EP 97921467 A EP97921467 A EP 97921467A EP 97921467 A EP97921467 A EP 97921467A EP 0921809 A4 EP0921809 A4 EP 0921809A4
Authority
EP
European Patent Office
Prior art keywords
prolactin
tgf
beta antagonist
antagonist
beta
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97921467A
Other languages
German (de)
French (fr)
Other versions
EP0921809A1 (en
Inventor
John J Mcpherson
Susan M Richards
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of EP0921809A1 publication Critical patent/EP0921809A1/en
Publication of EP0921809A4 publication Critical patent/EP0921809A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/225—Calcitonin gene related peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP97921467A 1996-04-30 1997-04-30 Use of prolactin as a tgf-beta antagonist Withdrawn EP0921809A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1649296P 1996-04-30 1996-04-30
PCT/US1997/007310 WO1997040848A1 (en) 1996-04-30 1997-04-30 Use of prolactin as a tgf-beta antagonist
US16492P 2007-12-24

Publications (2)

Publication Number Publication Date
EP0921809A1 EP0921809A1 (en) 1999-06-16
EP0921809A4 true EP0921809A4 (en) 2001-10-24

Family

ID=21777407

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97921467A Withdrawn EP0921809A4 (en) 1996-04-30 1997-04-30 Use of prolactin as a tgf-beta antagonist

Country Status (5)

Country Link
EP (1) EP0921809A4 (en)
JP (1) JP2000510112A (en)
AU (1) AU2749697A (en)
CA (1) CA2232682A1 (en)
WO (1) WO1997040848A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2526705T3 (en) 2005-10-25 2015-01-14 The Johns Hopkins University Methods and compositions for the treatment of Marfan syndrome and associated disorders
US8454952B2 (en) 2006-03-13 2013-06-04 The Johns Hopkins University Augmentation of endothelial thromboresistance
ES2647472T3 (en) 2006-10-03 2017-12-21 Genzyme Corporation Antibodies against TGF-BETA for use in the treatment of infants at risk of developing bronchopulmonary dysplasia
PT2835053T (en) 2010-03-12 2016-07-14 Genzyme Corp Combination therapy for treating breast cancer
KR20130131414A (en) 2010-12-27 2013-12-03 엘에스아이피 환도 운에이고우도우가이샤 Ips cells and method for generating same
EP2737083A1 (en) 2011-07-27 2014-06-04 INSERM (Institut National de la Santé et de la Recherche Scientifique) Methods for diagnosing and treating myhre syndrome
AU2011379972B2 (en) 2011-10-26 2016-05-12 Seattle Children's Research Institute Cysteamine in the treatment of fibrotic disease
ES2897740T3 (en) 2011-12-28 2022-03-02 Kyoto Prefectural Public Univ Corp Normalization of corneal endothelial cell culture
PL3064222T3 (en) 2013-10-31 2021-04-19 Kyoto Prefectural Public University Corporation Therapeutic drug comprising tgf-beta signal inhibitor for diseases related to endoplasmic reticulum cell death in corneal endothelium
US10882903B2 (en) 2015-05-18 2021-01-05 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods and compositions for treating an alphavirus infection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021625A1 (en) * 1994-02-14 1995-08-17 Genzyme Corporation Prolactin as a vaccine adjuvant

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995021625A1 (en) * 1994-02-14 1995-08-17 Genzyme Corporation Prolactin as a vaccine adjuvant

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DARCY KATHLEEN M ET AL: "Prolactin and epidermal growth factor regulation of the proliferation, morphogenesis, and functional differentiation of normal rat mammary epithelial cells in three dimensional primary culture.", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 163, no. 2, 1995, pages 346 - 364, XP001010464, ISSN: 0021-9541 *
RICHARDS S M ET AL: "Recombinant human prolactin is an antagonist of TGF-beta activity.", FASEB JOURNAL, vol. 10, no. 6, 30 April 1996 (1996-04-30), Joint Meeting of the American Society for Biochemistry and Molecular Biology, the American Society for Investigative Pathology and the American Association of Immunologists;New Orleans, Louisiana, USA, pages A1483, XP002172888, ISSN: 0892-6638 *
SANDI CARMEN ET AL: "Mutually antagonistic effects of corticosterone and prolactin on rat lymphocyte proliferation.", NEUROENDOCRINOLOGY, vol. 56, no. 4, 1992, pages 574 - 581, XP001010477, ISSN: 0028-3835 *
See also references of WO9740848A1 *
ZHU XIAO-HONG ET AL: "Prolactin inhibits the increased cytokine gene expression in Kupffer cells following haemorrhage.", CYTOKINE, vol. 8, no. 2, 1996, pages 134 - 140, XP001010309, ISSN: 1043-4666 *

Also Published As

Publication number Publication date
AU2749697A (en) 1997-11-19
EP0921809A1 (en) 1999-06-16
WO1997040848A1 (en) 1997-11-06
JP2000510112A (en) 2000-08-08
CA2232682A1 (en) 1997-11-06

Similar Documents

Publication Publication Date Title
HUP9700589A2 (en) Extended release formulation containing venlaflaxine hydrochloride
HK1018776A1 (en) Muscarinic antagonists
IL129423A0 (en) Improved preparation for use as contrast agent
HK1024484A1 (en) Thienopyrimidines having pde v-inhibiting action
IL130124A0 (en) Ketobenzamides as calpain inhibitors
AU3044197A (en) Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
ZA9710601B (en) Novel formulation
PL328921A1 (en) Pharmaceutically useful compounds
PL336348A1 (en) Indazolamide compounds as serotoninergic agents
GB2313596B (en) Novel buprenorphine analgesic analogues
AU4340497A (en) Golf accessory
PL330195A1 (en) Antagonist of dopamine d4 receptor
EP0921809A4 (en) Use of prolactin as a tgf-beta antagonist
GB9606016D0 (en) Novel use
IL126868A0 (en) Vial for use as syringe accessory
AU1846397A (en) Prolactin antagonists and uses thereof
ZA977491B (en) Use of polyhydroxycarboxylamides as EP additives.
ZA975805B (en) Virginiamycin mixture
GB9615628D0 (en) Formulation
GB2320039B (en) De-bonding sleeve
AU3852997A (en) Phenoxypropanolamines having beta3-adrenergic antagonist activity
NZ314277A (en) Octopeptide somatostatin antagonist
GB9621902D0 (en) Neurotrophin antagonist compositions
AU1794397A (en) Use of alpha1-adrenoceptor antagonists
GB9708766D0 (en) Fibrinogen receptor antagonist

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980902

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 38/17 A, 7A 61K 38/27 B, 7A 61K 38/22 B

A4 Supplementary search report drawn up and despatched

Effective date: 20010907

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20011221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20020501